左西孟旦在心力衰竭中的应用(2)
[2] Ponikowski P， Voors AA， Anker SD， et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure： The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC Eur Heart J， 2016， 37(27)： 2129-2200.
[3] Moiseyev VS， Poder P， Andrejevs N， et al. Safety and efficacy of a novel calcium sensitizer， levosimendan， in patients with left ventricular failure due to an acute myocardial infarction. A randomized， placebo-controlled， double-blind study (RUSSLAN). Eur Heart J， 2002， 23(18)： 1422-1432.
[4] Jia Z， Guo M， Zhang YQ， et al. Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction. Cardiology， 2014， 128(2)： 195-201.
[5] Comin-Colet J， Manito N， Segovia-Cubero J， et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure： the LION-HEART multicentre randomised trial. Eur J Heart Fail， 2018， 20(7)： 1128-1136.
[6] Silvetti S， Nieminen MS. Repeated or intermittent levosimendan treatment in advanced heart failure： An updated meta-analysis. Int J Cardiol， 2016， 202(1)： 138-143.
[7] Fotbolcu H， Duman D. A promising new inotrope： levosimendan. Anadolu Kardiyol Derg， 2010， 10(2)： 176-182., http://www.100md.com(黄蓉)
[3] Moiseyev VS， Poder P， Andrejevs N， et al. Safety and efficacy of a novel calcium sensitizer， levosimendan， in patients with left ventricular failure due to an acute myocardial infarction. A randomized， placebo-controlled， double-blind study (RUSSLAN). Eur Heart J， 2002， 23(18)： 1422-1432.
[4] Jia Z， Guo M， Zhang YQ， et al. Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction. Cardiology， 2014， 128(2)： 195-201.
[5] Comin-Colet J， Manito N， Segovia-Cubero J， et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure： the LION-HEART multicentre randomised trial. Eur J Heart Fail， 2018， 20(7)： 1128-1136.
[6] Silvetti S， Nieminen MS. Repeated or intermittent levosimendan treatment in advanced heart failure： An updated meta-analysis. Int J Cardiol， 2016， 202(1)： 138-143.
[7] Fotbolcu H， Duman D. A promising new inotrope： levosimendan. Anadolu Kardiyol Derg， 2010， 10(2)： 176-182., http://www.100md.com(黄蓉)